Key result
5HFeC nanoparticles boost MPI signal ~45%, effectively localizing vulnerable atherosclerotic plaques.
Why the study?
Current in vivo imaging modalities have low specificity and sensitivity for differentiating vulnerable atherosclerotic plaques from stable plaques, motivating the development of a multimodal imaging platform that targets active myeloperoxidase.
Do active myeloperoxidase-targeted 5-HT-Fe3O4-Cy7 nanoparticles (5HFeC NPs) accurately detect and localize vulnerable atherosclerotic plaques and monitor MPO activity in vivo using multimodal MPI/FLI/CTA imaging in mouse models?
Do active myeloperoxidase-targeted 5-HT-Fe3O4-Cy7 nanoparticles (5HFeC NPs) accurately detect and localize vulnerable atherosclerotic plaques and monitor MPO activity in vivo using multimodal MPI/FLI/CTA imaging in mouse models?
Answers are grounded in this paper and cite their sources.
Active MPO-targeted 5HFeC nanoparticles combined with multimodal MPI/FLI/CTA provide a sensitive, non-ionizing preclinical imaging approach to localize vulnerable atherosclerotic plaques and monitor plaque inflammation in vivo.
Inflammation is a pivotal driver of atherosclerotic plaque progression and rupture and is a target for identifying vulnerable plaques. However, challenges arise with the current in vivo imaging modalities for differentiating vulnerable atherosclerotic plaques from stable plaques due to their low specificity and sensitivity. Herein, we aimed to develop a novel multimodal imaging platform that specifically targets and identifies high-risk plaques in vivo by detecting active myeloperoxidase (MPO), a potential inflammatory marker of vulnerable atherosclerotic plaque. Methods: A novel multimodal imaging agent, 5-HT-Fe3O4-Cy7 nanoparticles (5HFeC NPs), used for active MPO targeting, was designed by conjugating superparamagnetic iron oxide nanoparticles (SPIONs) with 5-hydroxytryptamine and cyanine 7 N-hydroxysuccinimide ester. The specificity and sensitivity of 5HFeC NPs were evaluated using magnetic particle imaging (MPI), fluorescence imaging (FLI), and computed tomographic angiography (CTA) in an ApoE-/- atherosclerosis mouse model. Treatment with 4-ABAH, an MPO inhibitor, was used to assess the monitoring ability of 5HFeC NPs. Results: 5HFeC NPs can sensitively differentiate and accurately localize vulnerable atherosclerotic plaques in ApoE-/- mice via MPI/FLI/CTA. High MPI and FLI signals were observed in atherosclerotic plaques within the abdominal aorta, which were histologically confirmed by multiple high-risk features of macrophage infiltration, neovascularization, and microcalcification. Inhibition of active MPO reduced accumulation of 5HFeC NPs in the abdominal aorta. Accumulation of 5HFeC NPs in plaques enabled quantitative evaluation of the severity of inflammation and monitoring of MPO activity. Conclusions: This multimodal MPI approach revealed that active MPO-targeted nanoparticles might serve as a method for detecting vulnerable atherosclerotic plaques and monitoring MPO activity.
No takes yet. Share an insight, caveat, or question.
Tong et al. (2020) studied Vulnerable atherosclerotic plaque. 5-HT-Fe3O4-Cy7 nanoparticles (5HFeC NPs) with MPI/FLI/CTA imaging vs. Fe3O4-Cy7 nanoparticles, PBS-implanted control thigh, or MPO inhibition with 4-ABAH was evaluated on In vivo and ex vivo detection and localization of active myeloperoxidase (MPO) in vulnerable atherosclerotic plaques via MPI and FLI signal intensity (p=<0.001). 5HFeC nanoparticles increased MPI signal by 1.45-fold and fluorescence by 0.84-fold at 72 hours in MPO-implanted tissues and localized vulnerable aortic plaques in ApoE-/- mice.
Synapse has enriched 10 related papers. Consider them for comparative context: